DEVELOPMENT, CHARACTERIZATION AND OPTIMIZATION OF DOLUTEGRAVIR SOLID DISPERSIONS USING PEG 6000 AND PVP K30: COMPARATIVE PROCESSING, FACTORIAL DESIGN AND TABLET DEVELOPMENT
Background: Dolutegravir (DTG) is a potent HIV-1 integrase inhibitor with poor aqueous solubility, which can limit its dissolution and oral absorption. Objective: To develop and optimize dolutegravir solid dispersions using hydrophilic carriers for enhancement of solubility and dissolution. Methods: Solid dispersions w...